ConductScience.org, home

Paper40887107

HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions.

Okuyama K and 2 others. J Immunother Cancer, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions. Papers, record 40887107. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40887107

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions.
PubMed
Journal
J Immunother Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-09-05
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Okuyama KKoheihttps://orcid.org/0000-0002-5616-902X
2Fujimoto JJunya
3Yanamoto SSouichi

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Squamous Cell Carcinoma of Head and NeckMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Immune Checkpoint InhibitorsMajor topic
Head and Neck NeoplasmsMajor topic
Papillomavirus InfectionsMajor topic
PapillomaviridaeMajor topic
Humans

Source PubMed

Download CSV of topics

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127718784Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.N Engl J Med2016https://conductscience.org/library/papers/27718784PubMed
217548594Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity.J Immunol2007https://conductscience.org/library/papers/17548594PubMed
335727629Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.J Clin Invest2022https://conductscience.org/library/papers/35727629PubMed
436459926Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation.Semin Immunol2023https://conductscience.org/library/papers/36459926PubMed
537790755Cell-in-cell structure in cancer: evading strategies from anti-cancer therapies.Front Oncol2023https://conductscience.org/library/papers/37790755PubMed
639049036Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response.J Transl Med2024https://conductscience.org/library/papers/39049036PubMed
731679945
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet2019https://conductscience.org/library/papers/31679945PubMed
838942993Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial.Nat Med2024https://conductscience.org/library/papers/38942993PubMed
940143171Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40143171PubMed
1026373277FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.Cancer Cell2015https://conductscience.org/library/papers/26373277PubMed
1127777979The head and neck cancer immune landscape and its immunotherapeutic implications.JCI Insight2016https://conductscience.org/library/papers/27777979PubMed
1234083421Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.J Immunother Cancer2021https://conductscience.org/library/papers/34083421PubMed
1335803260Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.Cell2022https://conductscience.org/library/papers/35803260PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42482991Targeting innate immunity to overcome immune evasion in HPV-associated cancers.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42482991PubMed
41815129Transmembrane protein 9 as a novel biomarker promotes oral squamous cell carcinoma growth via IL1RN and serves as an immune therapeutic target.Transl Cancer Res2026https://conductscience.org/library/papers/41815129PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FCGR1A2209PubTator's text mininghttps://conductscience.org/library/genes/2209NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40887107

GET https://conductscience.org/api/papers/v1/40887107/authors